Literature DB >> 19627663

Sociology meets genetics: sociogenetic implications for future management of hypertension and heart failure.

Randy Wexler1, Adam Pleister, David Feldman.   

Abstract

Hypertension and heart failure contribute significantly to morbidity and mortality in the United States. Suboptimal control of these disease processes is multifactorial and involves poorly understood mechanisms affected by the environment (socioeconomic factors) and genetics (cell biology). Dietary sodium is an illustrative case. Although physicians intuitively accept that sodium affects renal and cardiovascular physiology, the complex overlay of genetics, environment, and culture is not practically addressed to make a meaningful difference in patient care. Optimal control of hypertension and heart failure will require a personalized care plan for each patient that includes lifestyle changes and carefully selected pharmacotherapy and also accounts for sociogenetic factors that affect each patient's life and thus his or her disease process. Physicians' cultural biases and perceptions also must be factored into this complex patient care equation.

Entities:  

Year:  2009        PMID: 19627663     DOI: 10.1007/s11936-009-0031-7

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  47 in total

1.  Reducing the population burden of cardiovascular disease by reducing sodium intake: a report of the Council on Science and Public Health.

Authors:  Barry D Dickinson; Stephen Havas
Journal:  Arch Intern Med       Date:  2007-07-23

2.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

3.  Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial.

Authors:  Lawrence J Appel; Catherine M Champagne; David W Harsha; Lawton S Cooper; Eva Obarzanek; Patricia J Elmer; Victor J Stevens; William M Vollmer; Pao-Hwa Lin; Laura P Svetkey; Sarah W Stedman; Deborah R Young
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

4.  Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.

Authors:  James B Young; Mark E Dunlap; Marc A Pfeffer; Jeffrey L Probstfield; Alain Cohen-Solal; Rainer Dietz; Christopher B Granger; Jaromir Hradec; Jerzy Kuch; Robert S McKelvie; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Peter Held; Scott D Solomon; Salim Yusuf; Karl Swedberg
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

5.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  The relationship between neighborhood characteristics and self-rated health for adults with chronic conditions.

Authors:  Arleen F Brown; Alfonso Ang; Anne R Pebley
Journal:  Am J Public Health       Date:  2007-03-29       Impact factor: 9.308

8.  Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony.

Authors:  C L Grines; T M Bashore; H Boudoulas; S Olson; P Shafer; C F Wooley
Journal:  Circulation       Date:  1989-04       Impact factor: 29.690

9.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

10.  Midterm benefits of left univentricular pacing in patients with congestive heart failure.

Authors:  Jean-Jacques Blanc; Valérie Bertault-Valls; Marjaneh Fatemi; Martine Gilard; Pierre-Yves Pennec; Yves Etienne
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.